Sumitomo Pharma (DB:DPM) - Aandelenkoers, Nieuws & Analyse

DPM Overzicht aandelen

DPM fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Verhandeld tegen 51.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 88.69% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Volatiele aandelenkoers in de afgelopen 3 maanden

Sumitomo Pharma Co., Ltd. Concurrenten

Dermapharm Holding

XTRA:DMP

€2.0b

PharmaSGP Holding

XTRA:PSG

€304.6m

Bayer

XTRA:BAYN

€19.0b

Apontis Pharma

XTRA:APPH

€82.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sumitomo Pharma
Historische aandelenkoersen
Huidige aandelenkoers	JP¥3.56
52 Week Hoogtepunt	JP¥4.22
52 Week Laag	JP¥1.64
Bèta	0.63
11 maand verandering	-3.26%
3 maanden verandering	-12.75%
1 Jaar Verandering	24.48%
33 jaar verandering	-65.44%
5 jaar verandering	-79.89%
Verandering sinds IPO	-62.53%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	DPM	DE Pharmaceuticals	DE Markt
7D	-2.7%	1.2%	1.3%
1Y	24.5%	-19.7%	7.9%

Rendement versus industrie: DPM overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -19.7 % opleverde.

Rendement versus markt: DPM overtrof de German markt, die het afgelopen jaar een rendement opleverde van 7.9 %.

Prijsvolatiliteit

Is DPM's price volatile compared to industry and market?
DPM volatility
DPM Average Weekly Movement	8.6%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van DPM is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van DPM is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1897	4,980	Toru Kimura	www.sumitomo-pharma.com

Sumitomo Pharma Co., Ltd. houdt zich bezig met de productie en verkoop van farmaceutische producten, voedingsingrediënten en -additieven, diergeneesmiddelen en andere producten in Japan, Noord-Amerika, China en internationaal. Het bedrijf biedt farmaceutische producten, zoals therapeutische middelen voor de ziekte van Parkinson, baarmoederfibromen, depressie, diabetes type 2, systemische schimmelinfectie, hoge bloeddruk, pruritus, gevorderde prostaatkanker, overactieve blaas, chronische obstructieve longziekte, angina pectoris en hartritmestoornissen. Het levert producten voor atypische antipsychotica, gekweekt thymusweefsel voor aangeboren athymie bij kinderen, anti-epileptica en antibiotica tegen carbapenem; en geneesmiddelen tegen de ziekte van Fabry.

Sumitomo Pharma Co., Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Sumitomo Pharma zich tot de beurswaarde?
DPM fundamentele statistieken
Marktkapitalisatie	€1.45b
Inkomsten(TTM)	-€1.75b
Inkomsten(TTM)	€2.14b

0.7x

P/S-verhouding

-0.8x

Koers/Winstverhouding

Is DPM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DPM resultatenrekening (TTM)
Inkomsten	JP¥342.67b
Kosten van inkomsten	JP¥138.58b
Brutowinst	JP¥204.08b
Overige uitgaven	JP¥483.54b
Inkomsten	-JP¥279.46b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Jan 31, 2025

Winst per aandeel (EPS)	-703.41
Brutomarge	59.56%
Nettowinstmarge	-81.55%
Schuld/Eigen Vermogen Verhouding	340.8%

Hoe presteerde DPM op de lange termijn?

Bekijk historische prestaties en vergelijking

DPM Overzicht aandelen

Beloningen

Risicoanalyse

Sumitomo Pharma Co., Ltd. Concurrenten

XTRA:DMP

€2.0b

XTRA:PSG

€304.6m

XTRA:BAYN

€19.0b

XTRA:APPH

€82.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

Second quarter 2025 earnings released: JP¥121 loss per share (vs JP¥72.68 loss in 2Q 2024)

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

New major risk - Share price stability

Recent updates

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

Second quarter 2025 earnings released: JP¥121 loss per share (vs JP¥72.68 loss in 2Q 2024)

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings released: EPS: JP¥40.11 (vs JP¥97.83 loss in 1Q 2024)

New minor risk - Share price stability

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings released: JP¥793 loss per share (vs JP¥188 loss in FY 2023)

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: JP¥126 loss per share (vs JP¥28.24 loss in 3Q 2023)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings released: JP¥72.68 loss per share (vs JP¥96.63 loss in 2Q 2023)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

New major risk - Share price stability

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Now 22% undervalued after recent price drop

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

New minor risk - Share price stability

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

Now 28% undervalued after recent price drop

First quarter 2024 earnings released: JP¥97.83 loss per share (vs JP¥78.30 profit in 1Q 2023)

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Full year 2023 earnings released: JP¥188 loss per share (vs JP¥142 profit in FY 2022)

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023

Third quarter 2023 earnings released: JP¥28.24 loss per share (vs JP¥24.94 profit in 3Q 2022)

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Mitsui & Co., Ltd. (TSE:8031) agreed to acquire Sumitomo Pharma Animal Health Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥96.63 loss per share (vs JP¥79.66 profit in 2Q 2022)

Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. Provides Impairment Loss Guidance for the Second Quarter of the Fiscal Year Ending March 31, 2023

Upcoming dividend of JP¥14.00 per share

Now 20% undervalued

Sumitomo Pharma Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥78.30 (vs JP¥12.09 in 1Q 2022)

Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023

Sumitomo Pharma Co., Ltd. to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings released: EPS: JP¥142 (vs JP¥142 in FY 2021)

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Less than half of directors are independent

Upcoming dividend of JP¥14.00 per share